Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07832461

ANCILLARY STUDY No. 3 NS-PARK-OMICS

The goal of this clinical study is to identify biomarkers associated with Parkinson's disease (PD) progression in PD patients, participants at-risk of developing PD (e.g., a person who does not have the disease but carrying a mutation known to be related to the disease or a person with a prodromal form as iRBD for example), as well as healthy volunteers. The working hypothesis of this study is that patients with Parkinson's disease can be stratified into etiological subgroups through the integration of omics data. Combining molecular signatures with longitudinal clinical and phenotypic data from the NS-PARK cohort will enable the development of disease progression models grounded in the pathophysiological mechanisms of Parkinson's disease. Researchers will compare the data with those from healthy volunteers to determine whether the findings are specific to PD, as some biomarkers may reflect broader processes related to neurodegeneration, aging, or comorbidities.

In this ancillary study, in addition to the NS-PARK cohort assessments, participants will be proposed to do, during one visit:

* A lumbar puncture * A blood draw * A urine collection * An olfactory test * A more detailed neuropsychological assessment

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut du Cerveau - ICM Hôpital Universitaire Pitié-Salpêtrière 47-83 Bd de l'Hôpital

Paris, 75013, France

Location contact

Pr Jean-Christophe CORVOL

CONTACT

[email protected]

+33 1 42 16 57 66

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

PATIENT GROUP -Enrolled in the NS-PARK cohort in the Parkinson's disease patient group, with sample collection for genetic analysis.

AT-RISK GROUP

-Enrolled in the at-risk group of the NS-PARK cohort, with sample collection for genetic analysis, in accordance with the NS-PARK cohort criteria, i.e.: Individual related to a patient with Parkinson's disease; And/or

  • Unaffected individual carrying a mutation in a gene known to be involved in Parkinson's disease; And/or
  • Individual presenting a prodromal form of the disease (e.g., idiopathic REM sleep behaviour disorder [iRBD]).

CONTROL GROUP (healthy volunteers)

  • Individual matched for age and sex with the patient included in this study;
  • No neurological disease or symptoms, as determined by the neurologist during the clinical interview, and no known history of neurological disease or symptoms.

FOR ALL GROUPS

  • Adult individual;
  • Affiliated with a social security scheme or entitled to benefits under such a scheme;
  • Negative blood or urine pregnancy test prior to inclusion for women of childbearing potential;
  • Having provided written, free and informed consent to participate in this research.

Exclusion criteria

  • Individuals under judicial protection (sauvegarde de justice);
  • Pregnant or breastfeeding women;
  • Individuals under guardianship or curatorship;
  • Known contraindication to lumbar puncture (as defined in the protocol).

Treatment and study plan

Lumbar Puncture

Procedure

A 15 mL cerebrospinal fluid (CSF) sample will be collected from each participant by lumbar puncture (LP) for research purposes, after confirming the absence of any contraindications. The LP will be performed by an experienced physician, with the participant lying down. An atraumatic needle and catheter will be used to minimize the risk of post-lumbar puncture syndrome. The sample will be collected using standard equipment.

Primary outcomes

  1. Biomarkers associated with PD progression

    Time frame: At inclusion

    Biomarker levels measured in biological fluids

Study contacts

Contact information is provided by the study sponsor or research team.

Pr Jean-Christophe CORVOL

CONTACT

[email protected]

+33 1 42 16 57 66

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Official study title

ANCILLARY STUDY No. 3 TO RIPH C16-56: THE NS-PARK COHORT AIMED AT IDENTIFYING BIOMARKERS FOR PARKINSON'S DISEASE

Acronym: NS-PARK-OMICS

Important dates

Study start
2026
Primary completion
2032
Study completion
2033
First posted
Sep 22, 2026
Registry last updated
Sep 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.